CGT

Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Jeudi, mai 9, 2024
Mouse, CRISPR, Impact, Compact, Gene editing, Cell, Artificial intelligence, CGT, PCSK9, IND, CNS, TDP43, PH1, Therapy, Patient, Liver, Gene, Society, ALS, Brain cell, Central nervous system, Messenger, HAO1, NHP, Annual general meeting, Pharmacology, Engineering, Medical device

“This approach has fueled our robust pipeline of genetic medicines which address a range of liver and CNS indications, including PH1 and ALS.

Key Points: 
  • “This approach has fueled our robust pipeline of genetic medicines which address a range of liver and CNS indications, including PH1 and ALS.
  • The data show highly specific targeting of the HAO1 gene in the liver and preservation of genomic integrity upon editing.
  • Together, this strong preclinical data package and the ongoing IND-enabling studies support continued advancement of ABO-101 toward clinical evaluation.
  • Details for the presentations are as follows:
    Oral Presentation Title: Identification and Engineering of ABR-004, a Compact, High-fidelity Nuclease for Therapeutic Gene Editing

Rogers $1M Season of Canada’s Got Talent: CGT Reveals the First Six Performers Heading to the Finale, May 14 on Citytv

Retrieved on: 
Mercredi, mai 8, 2024
Hatred, Prince Albert, Humour, ABBA, MAT, MYM, AB, CGT, Mission, Was, Kardinal Offishall, Toronto Maple Leafs, CIBC, Sterling, TROY, Lilly, Sand, Entertainment

TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- On tonight’s episode of Canada’s Got Talent on Citytv, the #CGT judges – Howie Mandel, Lilly Singh, Trish Stratus, Kardinal Offishall – and host Lindsay Ell selected the first six of eight acts moving on to the live two-hour finale, airing Tuesday, May 14 at 8 p.m. ET / 5 p.m. PT on Citytv and Citytv+. They are:

Key Points: 
  • ET / 5 p.m. PT on Citytv and Citytv+.
  • ET / 1 a.m. PT to vote two additional acts from tonight’s episode into the finale at www.Citytv.com/vote .
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.

Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit

Retrieved on: 
Mercredi, mai 8, 2024
FDA, Health, Genetics, Pharmaceutical, Clinical Trials, Ecosystem, Regenerative medicine, Food, Cell, Research, ARM, CGT, Patient, Gene, Clinical trial, Pharmaceutical industry

Cencora , a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit , an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.

Key Points: 
  • Cencora , a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit , an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.
  • “We are entering a new era in cell and gene therapy — with new modalities reaching the market and a growing number of products in clinical development, including therapies that target larger patient populations.
  • However, the path to commercialization is complex and lined with potential challenges that can impact product success and patient access,” said Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at Cencora.
  • Through its CGT Integration Hub , Cencora connects provider-facing platforms with patient services support programs to increase visibility across the therapy development and delivery process, streamlining the path-to-care.

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

Retrieved on: 
Lundi, mai 6, 2024
Messenger, DNA, Research Triangle Park, Triangle Park (Quezon City), Research, Organization, AAV, CGT, NGS, Pharmaceutical industry

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.

Key Points: 
  • KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
  • It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
  • It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities.
  • From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

Retrieved on: 
Lundi, mai 6, 2024
Messenger, DNA, Research Triangle Park, Triangle Park (Quezon City), Research, Organization, AAV, CGT, NGS, Pharmaceutical industry

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.

Key Points: 
  • KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
  • It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
  • It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities.
  • From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.

BioIVT Highlights its Focus on Cell and Gene Therapy in Spring Industry Events

Retrieved on: 
Lundi, mai 6, 2024
International Society, QA/QC, Cell, CGT, Different, Gene, Society, ISCT, Supply chain, Medical device

"At BioIVT, we view cell and gene therapy as a masterpiece in the making with dedicated researchers serving as the artists behind the canvas, and we are proud to provide the essential materials and the spark of inspiration for the next research breakthroughs," said Jain. "Our fit-for-purpose solutions provide flexibility in the supply chain to mitigate risks to our customers' CGT pipeline--from R&D through clinical phases of development. We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

Key Points: 
  • WESTBURY, N.Y., May 6, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will be attending two leading industry events focused on cell and gene therapy research, developments and breakthroughs.
  • From May 7 – 11, a team from BioIVT will attend the American Society of Gene and Cell Therapy Annual Meeting (ASGCT) in Baltimore and from May 29 – June 1, a team will attend the International Society of Cell and Gene Therapy Annual Meeting (ISCT) in Vancouver, Canada.
  • BioIVT will have a booth at each event detailing the art of cell and gene therapy, which highlights how BioIVT provides researchers with the resources necessary to develop and fuel their next breakthroughs.
  • We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

Retrieved on: 
Mardi, avril 30, 2024
BLFS, Webcast, CGT

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.

Key Points: 
  • BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.
  • The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day.
  • Management will provide an overview of the Company's financial results and give a general business update.
  • To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings.

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024

Retrieved on: 
Mercredi, avril 24, 2024
Debt-to-GDP ratio, Element, Acceleration, Probability, Depreciation, Security (finance), Convertible, CGT, Forecasting, CDMO, Environment, Operating cost, Acquisition, Quarter, Name, Biotechnology, GAAP, Note, Video game

TUSTIN, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the third quarter and nine months ended January 31, 2024.

Key Points: 
  • Highlights from the Quarter Ended January 31, 2024, and Other Events:
    "I would first like to address the reasons for our delayed 10-Q filing for the third quarter of fiscal 2024,” stated Nick Green, president and CEO of Avid Bioservices.
  • “I will now turn to the positive results for our third quarter and first nine months of fiscal 2024.
  • “During the third quarter we had stronger revenues and an increase in bookings as compared to Q2 2024.
  • More detailed financial information and analysis may be found in Avid Bioservices’ Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission today.

Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Lundi, avril 22, 2024
CRISPR, Impact, Compact, Cell, CGT, PCSK9, PH1, STMN2, Liver, Gene, Society, ALS, Messenger, HAO1, NHP, Engineering, Medical device

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced four upcoming presentations at the 2024 American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11 in Baltimore, Maryland.

Key Points: 
  • Arbor will present in vivo NHP data supporting clinical development of ABO-101, its most advanced gene editing therapeutic candidate designed to address primary hyperoxaluria type 1 (PH1) through inactivation of the HAO1 gene in the liver.
  • The company also will present data supporting its end-to-end nuclease development platform in a third presentation outlining the discovery and optimization of a unique, compact nuclease, termed ABR-004.
  • Proof-of-concept data in non-human primates show potent, therapeutically relevant silencing of PCSK9 in vivo with the novel nuclease, signaling opportunities for broader therapeutic applications.
  • Together, the suite of presentations will demonstrate the utility of Arbor’s proprietary discovery and development approach for enabling efficient identification and optimization of novel nucleases.

Rogers $1M Season of Canada’s Got Talent: Top Performances from Tonight’s Episode on Citytv

Retrieved on: 
Mercredi, avril 17, 2024
EVE, Labrinth, SOON, Disability, SAM, Animal, AB, CGT, NOAH, QC, Cat, CIBC, Omnichord, Lilly, Maple, Nightclub

82-year-old SOON KEUN KWON (Mississauga, ON) received a standing ovation after wow’ing the crowd with his incredible drum playing.

Key Points: 
  • 82-year-old SOON KEUN KWON (Mississauga, ON) received a standing ovation after wow’ing the crowd with his incredible drum playing.
  • Every Golden Buzzer recipient will receive $25,000 (totalling $150,000), courtesy of CIBC, to help realize their ambitions.
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.